Tools
Stock profile

Embecta Corp. (EMBC)

EMBC · Latest close $6.09 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$6.09
As of Nov 18, 2026
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
0 / 1
vs previous quarter
Trimmed / exited
2
vs previous quarter

Embecta Corp. (EMBC) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $37.0K sold). Latest close $6.09 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 4, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-37.0K
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Yacktman Asset Management · Deerfield Management — 2 tracked funds hold EMBC. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 1 sale ($37.0K). Insider trading

Often held alongside

BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Yacktman Asset Management0.17%4,315,952ADDED (+17.5%) Q3 filed Nov 2
Deerfield Management0.09%2,534,961HELD Q3 filed Nov 16
Tweedy Browne——EXITED
Rubric Capital Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +83.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

20.932.182024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding320 of 8,857 filers
Long-only filers among them319
Change vs 2026 Q1-10 net · 305 entered · 315 exited
Shares reported, all filers50,340,648
Reported value, all filers$155.3M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustrySurgical & Medical Instruments & Apparatus (SIC 3841)
Revenue · FY2025$1.1B
Net income · FY2025$95.4M
Total assets · FY2025$1.1B
Shares outstanding56,659,599
Market cap (at latest close)$345.1M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 20265,870,247
Share of shares outstanding10.36%
Days to cover6.16

Shares short at recent settlements — Jul 31, 2026: 6.7M · Aug 14, 2026: 5.4M · Aug 31, 2026: 6.3M · Sep 15, 2026: 5.5M · Sep 30, 2026: 5.8M · Oct 15, 2026: 5.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 3K · Sep 30, 2026: 681 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($37.0K).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Sep 4, 2026Morris Milton MayoSell6,293$5.88$37.0KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 4, 2026Morris Milton MayoDirector6,293$36.9KSep 4, 2026SEC filing
Feb 13, 2025Morris Milton MayoDirector3,100$50.8KFeb 13, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026SC 13G/A———SEC filing
Jul 8, 2026BlackRock, Inc.SC 13G/A4,554,3947.7%Jun 30, 2026SEC filing
May 27, 2026River Road Asset Management, LLCSC 13G/A00.0%May 26, 2026SEC filing
May 5, 2026YACKTMAN ASSET MANAGEMENT LPSC 13G3,671,8776.2%Mar 31, 2026SEC filing
May 1, 2026SC 13G/A———SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G3,004,5015.1%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jan 30, 2026The Vanguard GroupSC 13G/A4,617,6107.8%Dec 31, 2025SEC filing
Aug 14, 2025American Century Capital Portfolios, Inc.SC 13G/A3,460,3795.9%Jun 30, 2025SEC filing
Jul 29, 2025The Vanguard GroupSC 13G/A5,466,6049.3%Jun 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Insiders

· Opportunistic Buys (Non-Routine) — Last 90 days: 2 or more insiders with no routine buying pattern bought on the open market

Financial Screens

· Graham — Sound finances and a long run of profits

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

· Shareholder Yield — Cash returned through dividends and buybacks

Chart Signals

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Late Filings (NT) — Last 2 years: a late-filing notification (NT form)

Key figures

· Graham — Current ratio: 2.41 · Straight profitable years: 6 · Debt ratio: — · Latest net income: $95.4M

· Cash Flow (FCF) — Latest FCF: $182.4M · FCF yield: 47.2% · Positive FCF years: 3

· Gross Profitability (Novy-Marx) — Gross profit / assets: 62.0% · Gross margin: 62.6%

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.14 · Operating cash flow: $191.7M · Net income: $95.4M

· Shareholder Yield — Shareholder yield: 9.1% · of which dividends: 9.1% · of which buybacks: 0.0%

· Opportunistic Buys (Non-Routine) — Opportunistic buyers: 4 · Buy txns: 4 · Buy value: $557.9K · Latest buy: Aug 12, 2026

· Late Filings (NT) — Latest event: Nov 29, 2024 · Events in 2 yrs: 1 · Latest form: NT 10-K

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q3, ranked #17 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together10.0%-27.3%+2.9%-30.2%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold EMBC — ranked by lift, the co-holding pattern described in Methodology: BECTON DICKINSON & CO (BDX) · BOSTON SCIENTIFIC CORP (BSX) · BAXTER INTERNATIONAL INC (BAX) · STRYKER CORP (SYK) · Solventum Corp (SOLV) · Medline Inc. (MDLN) · 3M CO (MMM) · WEST PHARMACEUTICAL SERVICES INC (WST).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Aug 7, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jul 31, 2026 · 8-K/A9.01 Financial Statements and ExhibitsSEC filing
May 15, 20262.01 Completion of Acquisition or Disposition of Assets · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

BECTON DICKINSON & CO (BDX) · Track Record: how the signals scored · Practice timing on EMBC

One email a week: the week’s new filings and research. Subscribe free

← ELVN  ·  EMBJ →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.